{"commentary":{"count":118,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":49,"x_thread":45,"podcast":24},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04919512\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SunRISe-4","nct_id":"NCT04919512","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sunrise-4-nct04919512. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"SunRISe-4","arms":[{"description":"Participants will receive TAR-200 in combination with cetrelimab.","label":"Cohort 1: TAR-200 + Cetrelimab","type":"EXPERIMENTAL"},{"description":"Participants will receive cetrelimab.","label":"Cohort 2: Cetrelimab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-03-31","type":"ACTUAL"},"conditions":["Urinary Bladder Neoplasms"],"enrollment":{"count":163,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"TAR-200","type":"DRUG"},{"name":"Cetrelimab","type":"BIOLOGICAL"}],"last_update":"2026-06-23","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-02-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Pathologic Complete Response (pCR) Rate","timeFrame":"At Week 12"}],"references":[{"citation":"Necchi A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, Garje R, Szabados B, Peyton CC, Pradere B, Ku JH, Shore N, Bogemann M, Preston MA, Xylinas E, Sanchez de Llano C, Gong C, Hasan M, Urtishak K, Battaglia S, Stitou H, Bhanvadia S, Sweiti H, Psutka SP. Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results. J Clin Oncol. 2026 Mar;44(7):586-597. doi: 10.1200/JCO-25-02382. Epub 2025 Dec 3.","pmid":"41337691","type":"DERIVED"},{"citation":"Necchi A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, Garje R, Powles T, Peyton CC, Pradere B, Ku JH, Shore N, Bogemann M, Preston MA, Xylinas E, Sanchez de Llano C, Hasan M, Stitou H, Bhanvadia S, Sweiti H, Psutka SP. TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial. Lancet Oncol. 2025 Oct;26(10):1312-1322. doi: 10.1016/S1470-2045(25)00358-4. Epub 2025 Aug 27.","pmid":"40885199","type":"DERIVED"}],"start_date":{"date":"2022-07-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder","url":"https://clinicaltrials.gov/study/NCT04919512"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sunrise-4-nct04919512"}